Eterna Therapeutics Inc (ERNA) Stock Analysis

Eterna Therapeutics Inc (ERNA) is a publicly traded company in the HEALTHCARE sector. It trades at $8.00, carries a market capitalization of $10.64M, a price-to-earnings ratio of 0.01. This page summarizes the public market data, fundamentals, and frequently asked questions for ERNA, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Eterna Therapeutics Inc currently has a Bullish sentiment score of 0.25.

About Eterna Therapeutics Inc

Eterna Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Brooklyn, New York, dedicated to advancing innovative immunotherapy solutions to address critical unmet needs in cancer treatment. By harnessing cutting-edge technology platforms, Eterna aims to redefine the therapeutic landscape and improve patient outcomes in oncology. With a robust commitment to research and strategic collaborations, Eterna is positioned to deliver significant advancements and value wit...

GNG Research Analysis

GNG Research scores Eterna Therapeutics Inc (ERNA) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for ERNA.

Frequently Asked Questions

Does ERNA pay dividends?

Eterna Therapeutics Inc (ERNA) does not currently pay a regular dividend.

What is ERNA's P/E ratio?

Eterna Therapeutics Inc has a price-to-earnings (P/E) ratio of 0.01.

What is ERNA's market cap?

Eterna Therapeutics Inc (ERNA) has a market capitalization of $10.64M with a current stock price of $8.00.